enfortumab vedotin-ejfv
FDA Approves Padcev with Keytruda for Locally Advanced or Metastatic Urothelial Cancer
The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, ...
DECEMBER 17, 2023
Study Provides New First-Line Standard for Advanced Bladder Cancer
Clinicians have a new first-line standard for advanced bladder cancer, according to an international phase 3 study, ...
NOVEMBER 7, 2023
Padcev With Keytruda Approved for Locally Advanced or Metastatic Urothelial Carcinoma
The FDA gave accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas Pharma) with pembrolizumab ...
APRIL 5, 2023
Padcev Granted Regular Approval for Locally Advanced or Metastatic UC
The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) to treat some adults with locally advanced or ...
JULY 19, 2021
Padcev Approved for Some Patients With Locally Advanced or Metastatic Bladder Cancer
The FDA granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas/Seattle Genetics) for the ...
DECEMBER 20, 2019
